Calendar

The earnings reaction was positive but uneven: PEBO closed at $37.56 on October 20 versus $36.47 before the release, dipped to $37.33 on October 21, then reached the packet's $38.19 adjusted-close anchor on October 22 [historical prices](https://mx.investing.com/equities/peoples-bancorp-inc-historical-data). One reported post-print target increase is constructive, but comprehensive estimate revisions remain unavailable. The stored 'earnings document' concerns TCBX, not PEBO, and was excluded. Strong Q3 primary evidence raises confidence relative to the April baseline, while the deterministic negative directional prior and pending-deal risk argue against upgrading beyond cautious monitoring.

News tone turned negative after the miss. PEGA closed October 21 at $35.18, down 2.9% from its October 20 close, then reached the packet's $36.65 October 22 anchor; the initial decline did not persist through T+2. [Historical prices](https://markets.ft.markitdigital.com/data/equities/tearsheet/historical?s=PEGA%3ANSQ) Post-print analyst targets moved in both directions, so revision evidence remains mixed. Social, options, short-interest, and employee-sentiment readings were not supplied; zero placeholders above do not represent measured observations.

Zacks reported a 4.2% gain on October 21 after the EPS beat; the packet's October 22 close of $49.67 shows the initial reaction held through the next session. That is a price observation, not confirmation of the 2027 outlook. No reliable post-print analyst target or rating revision was verified. The zero-valued social, options, short-interest, employee, and news-sentiment fields mean unavailable, not neutral readings. The deterministic prior shifted positive on the scheduled earnings trigger, but its 0.08 evidence-quality score and the absence of verified revisions argue against a high-conviction upgrade. [Zacks market reaction](https://www.zacks.com/stock/news/3012374/company-news-for-oct-22-2026)

The Q3 release and reported EPS beat improved the operating evidence versus the April baseline, and ORRF rose about 5.3% from its October 20 close to the October 22 anchor. That reaction held through T+3, but verified named analyst target or estimate revisions remain unavailable; absent revisions are not a positive signal. The deterministic delta prior is negative despite high evidence quality, consistent with caution about funding and tangible-book pressure after the rally. The sentiment numeric fields other than headline buzz are unmeasured, not estimates. https://chartexchange.com/symbol/nasdaq-orrf/historical/; [#SEC-8K-2026-10-21]

The company released third-quarter earnings on October 15, although the follow-up queue labels October 20 as the earnings date. Shares closed at $23.55 on October 16, down 3.6% the day after the release, then reached the packet's $24.20 October 22 anchor; the recovery cannot be attributed solely to the merger vote. [Historical prices](https://chartexchange.com/symbol/nasdaq-nrim/historical/). Company evidence is strong, but analyst coverage and revision data are thin. The unavailable social, options, short-interest and employee measures shown as zero are placeholders, not neutral observations. The deterministic prior remains negative, so the thesis stays monitoring-oriented despite shareholder approval.

The October 22 company release is the substantive new evidence; the scheduled trigger's October 20 earnings date does not match the release date. The $15.02 anchor is the October 22 close and cannot establish a post-release reaction. Verified October 23 price follow-through and post-print analyst revisions were unavailable. Consensus sources disagree, and the zero-valued social, options, short-interest and employee fields denote unavailable data rather than neutral readings. The deterministic prior is positive, but higher credit costs keep this a cautious monitoring view. [#SEC-8K-2026-10-22]